Wednesday, July 2, 2025

Invetech & AiCella Partner to Advance Cell Therapy Innovation

Related stories

Blaize Raises $56M for Edge AI in Southeast Asia’s Infra

Blaize, a leader in edge AI computing, has secured...

Formant F3 Adds Gen AI, Agentic Reasoning to Robot Ops

Formant has announced the debut of F3, an AI-native...

CustomerInsights.AI Launches ciATHENA, an AI Platform for Pharma Analytics

CIAI announced the launch of ciATHENA, a next generation Agentic...

PhaseV Unveils ClinOps AI for Smarter Trial Site Picks

Powered by Causal AI and Real-Time Patient-Level Data and...

Accenture Acquires SYSTEMA to Boost Semiconductor Automation

Accenture has acquired SYSTEMA, a provider of software solutions...
spot_imgspot_img

Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, announced a strategic collaboration with AiCella, a company focused on harnessing the power of artificial intelligence (AI) to optimize the development of cell therapy production processes and maximize patient response to treatment.

This partnership brings together Invetech’s deep domain expertise in End-to-End custom automation with AiCella’s cutting-edge artificial intelligence platform to deliver smarter, faster, and more cost-effective solutions for the industry – accelerating innovation and improving outcomes across the cell therapy landscape.

Also Read: Causaly Launches AI Competitive Intelligence for Scientists

“This collaboration is about more than just combining technologies—it’s about solving some of the most persistent challenges in cell therapy production,” said Andreas Knaack, President of Invetech. “By integrating AiCella’s predictive AI models with our proven technology platforms, we aim to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and ultimately accelerate the path to scalable, patient-ready therapies.”

“Our goal at AiCella is to uncover the hidden relationships between process inputs and patient outcomes—insights that traditional methods often miss,” said Geoffrey Stephens, PhD, CEO and Founder of AiCella. “Through this collaboration with Invetech, we’re embedding our AI models directly into the development and manufacturing lifecycle. This allows us to not only optimize process performance but also to generate data-driven hypotheses about which parameters most influence therapeutic efficacy—bringing us closer to truly personalized, responsive cell therapies.”

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img